Advertisement

Advertisement

TARA Stock Latest News

Protara Therapeutics price target raised to $28 from $25 at Oppenheimer

The FlyProtara Therapeutics price target raised to $28 from $25 at Oppenheimer

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

PremiumRatings

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

11d ago

Unusually active option classes on open May 15th

PremiumThe Fly

Unusually active option classes on open May 15th

15d ago

Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial

PremiumThe Fly

Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial

15d ago

Protara Therapeutics price target lowered to $26 from $27 at JPMorgan

PremiumThe Fly

Protara Therapeutics price target lowered to $26 from $27 at JPMorgan

16d ago

Protara Therapeutics files $300M mixed securities shelf

PremiumThe FlyProtara Therapeutics files $300M mixed securities shelf

17d ago

Protara Therapeutics reports Q1 EPS (31c), consensus (37c)

The Fly

Protara Therapeutics reports Q1 EPS (31c), consensus (37c)

17d ago

JPMorgan healthcare analysts hold an analyst/industry conference call

The Fly

JPMorgan healthcare analysts hold an analyst/industry conference call

2M ago

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

PremiumCompany Announcements

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

2M ago

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

PremiumRatings

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

2M ago

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

PremiumRatings

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

3M ago

Protara Therapeutics reports Q4 EPS (37c), consensus (31c)

PremiumThe Fly

Protara Therapeutics reports Q4 EPS (37c), consensus (31c)

3M ago

Protara Therapeutics sees cash runway into 2028

PremiumThe FlyProtara Therapeutics sees cash runway into 2028

3M ago

TARA Upcoming Earnings Report: What to Expect?

Pre-Earnings

TARA Upcoming Earnings Report: What to Expect?

3M ago

De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara

Ratings

De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara

3M ago

Protara Therapeutics initiated with an Overweight at JPMorgan

PremiumThe Fly

Protara Therapeutics initiated with an Overweight at JPMorgan

3M ago

Protara Highlights Strong Phase 2 Data for TARA-002

PremiumCompany Announcements

Protara Highlights Strong Phase 2 Data for TARA-002

3M ago

Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC

PremiumRatings

Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC

3M ago

Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer

PremiumRatings

Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer

3M ago

Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months

PremiumThe FlyProtara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months

3M ago

Protara Therapeutics management to meet with Oppenheimer

The Fly

Protara Therapeutics management to meet with Oppenheimer

4M ago

Protara Therapeutics highlights recent updates, 2026 milestones

The Fly

Protara Therapeutics highlights recent updates, 2026 milestones

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >